Breaking news

SK Hynix Profit Surges As AI Demand Boosts Memory Prices

A South Korean memory chipmaker SK Hynix reported another quarter of strong profits and revenue, supported by demand for artificial intelligence and higher memory prices. Results were broadly in line with expectations, although revenue came in slightly below forecasts, reflecting shifting market conditions.

Record-Breaking Earnings And Market Momentum

Revenue reached 52.58 trillion won (approximately $35.55 billion), slightly below the forecast of 53.55 trillion won. Operating profit came in at 37.61 trillion won, compared with an expected 37.92 trillion won. On an annual basis, revenue nearly tripled while operating profit increased fivefold. The operating margin rose to 72%, reflecting stronger pricing and sustained demand.

Early trading gains in South Korea followed the results, indicating positive investor sentiment. The company linked performance to rising memory prices and continued investment in AI infrastructure, with customers prioritizing supply stability.

Dram Market Duel And Strategic Positioning

Data from Counterpoint Research show that the DRAM market recorded around 30% sequential growth in recent quarters, driven by pricing and limited capacity. Competition remains active between Micron Technology and Samsung Electronics. SK Hynix has focused on high-bandwidth memory (HBM), a key component for AI data centers.

The company holds roughly 57% of the HBM market. While Samsung regained the lead in overall DRAM revenue in late 2025, SK Hynix maintains a strong position in HBM. Plans include releasing HBM4E samples later this year, with mass production expected in 2027.

Capacity Constraints And Supply Chain Diversification

Industry commentary suggests supply constraints may persist. Chey Tae-won stated that wafer shortages could continue until 2030, with capacity expansion requiring several years and potentially leaving gaps in supply. In response, SK Hynix is investing 19 trillion won in a new manufacturing facility in South Korea. Additional steps include diversifying suppliers and securing long-term energy agreements to manage cost volatility.

Outlook

Demand linked to AI development continues to support the memory market, although pricing trends may moderate later in the year. Strong profitability, combined with ongoing investment in capacity and technology, positions SK Hynix to remain competitive as market conditions evolve.

Colossal Biosciences Seeks Funding At Up To $30 Billion Valuation

Colossal Biosciences, the biotechnology startup known for its efforts to revive extinct species including the woolly mammoth and dire wolf, is in talks to raise funding at a valuation of $20 billion to $30 billion, according to Axios.

The company was last valued at $10.2 billion in a January funding round. It has since begun generating revenue, Axios reported, although neither the size of the new financing nor its potential investors have been disclosed.

Business Extends Beyond De-Extinction

While Colossal has attracted global attention for its de-extinction projects, the company is also building a broader biotechnology business around the tools developed through that research.

Co-founder and Chief Executive Ben Lamm has said Colossal expects revenue from three areas: conservation technologies, new businesses created from its research and future commercial applications of technologies developed alongside its de-extinction programme.

Expanding Commercial Portfolio

Colossal has already supplied conservation technology to the U.S. government and the United Arab Emirates, which recently invested $60 million in the company, according to Wired.

Its research has also led to the creation of several startups, including plastics recycling company Breaking, computational biology platform Form Bio, which raised $30 million, and AI-driven biology company Astromech, which was valued at $2 billion in March.

Research Continues To Expand

Operating from a 55,000-square-foot facility in Dallas, Colossal continues to broaden its research portfolio.

In April, the company added the bluebuck antelope as its sixth de-extinction target. More recently, the Colossal Foundation partnered with the University of Tasmania to develop vaccines and gene-editing approaches aimed at protecting Tasmanian devils from a contagious facial cancer.

Lamm has also said the company plans to spin out its artificial womb technology, which could eventually have applications in fertility treatment. Speaking to Rolling Stone in May, he said the technology could be ready next year.

Investor Interest In Deep Tech

The fundraising discussions come as investors increase spending on sectors such as biotechnology, longevity and other deep-tech fields.

Lamm has also said Colossal could eventually generate revenue from biodiversity credits if restored species are successfully reintroduced into their natural habitats, creating another potential commercial opportunity.

eCredo
Aretilaw firm
The Future Forbes Realty Global Properties
Uol

Become a Speaker

Become a Speaker

Become a Partner

Subscribe for our weekly newsletter